The influence of ionotropic and metabotropic glutamate receptor ligands on anxiety-like effect of amphetamine withdrawal in rats

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 45, Issue , 2013, Pages 242-249

  Koltunowska, D ^a   Gibula Bruzda, E ^a   Kotlinska, J H ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Acamprosate Amphetamine withdrawal Anxiolytic like activity LY354740 Memantine MTEP; Acamprosate; Amphetamine withdrawal; Anxiolytic like activity; LY354740; Memantine; MTEP

Indexed keywords

3 [(2 METHYL 4 THIAZOLYL)ETHYNYL]PYRIDINE; ACAMPROSATE; AMPHETAMINE; EGLUMETAD; GLUTAMIC ACID; IONOTROPIC RECEPTOR; MEMANTINE; METABOTROPIC RECEPTOR; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DRUG DEPENDENCE; EVOKED RESPONSE; LOCOMOTION; MALE; MAZE TEST; NONHUMAN; RAT; RELAPSE; TRANQUILIZING ACTIVITY; WITHDRAWAL SYNDROME;

Α-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID; Γ-AMINOBUTYRIC ACID; ACAMPROSATE; AMPA; AMPHETAMINE WITHDRAWAL; ANALYSIS OF VARIANCE; ANOVA; ANXIOLYTIC-LIKE ACTIVITY; GABA; IGLURS; INTRAPERITONEAL INJECTION; IONOTROPIC GLUTAMATE RECEPTORS; IP; LY354740; MEMANTINE; METABOTROPIC GLUTAMATE RECEPTORS; MGLURS; MTEP; N-METHYL-D-ASPARTATE; NMDA; SEM; STANDARD ERROR OF THE MEAN;

AMPHETAMINE; ANIMALS; ANXIETY; BICYCLO COMPOUNDS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID AGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; LIGANDS; MALE; MEMANTINE; PYRIDINES; RATS; RECEPTORS, IONOTROPIC GLUTAMATE; RECEPTORS, METABOTROPIC GLUTAMATE; SUBSTANCE WITHDRAWAL SYNDROME; TAURINE; THIAZOLES;

EID: 84880008120     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2013.04.013     Document Type: Article

References (75)

1. Amit Z., Smith B.R. Remoxipride, a specific D2 dopamine antagonist: an examination of its self-administration liability and its effects on d-amphetamine self-administration. Pharmacol Biochem Behav 1992, 41:259-261.
2. Anderson J.J., Bradbury M.J., Giracello D.R., Chapman D.F., Holtz G., Roppe J., et al. In vivo receptor occupancy of mGlu5 receptor antagonists using the novel radioligand [3H]3-methoxy-5-(pyridin-2-ylethynyl)pyridine). Eur J Pharmacol 2003, 473:35-40.
3. Barr A.M., Markou A. Psychostimulant withdrawal as an inducing condition in animal models of depression. Neurosci Biobehav Rev 2005, 29:675-706.
4. Barr A.M., Markou A., Phillips A.G. A 'crash' course on psychostimulant withdrawal as a model of depression. Trends Pharmacol Sci 2002, 23:475-482.
5. Bergink V., van Megen H.J., Westenberg H.G. Glutamate and anxiety. Eur Neuropsychopharmacol 2004, 14:175-183.
6. Berman S.M., Kuczenski R., McCracken J.T., London E.D. Potential adverse effects of amphetamine treatment on brain and behavior: a review. Mol Psychiatry 2009, 14:123-142.
7. Bertoglio L.J., Carobrez A.P. Anxiolytic-like effects of NMDA/glycine-B receptor ligands are abolished during the elevated plus-maze trial 2 in rats. Psychopharmacology 2003, 170:335-342.
8. Bespalov A.Y., Zvartau E.E., Balster R.L., Beardsley P.M. Effects of N-methyl-d-aspartate receptor antagonists on reinstatement of cocaine-seeking behavior by priming injections of cocaine or exposures to cocaine-associated cues in rats. Behav Pharmacol 2000, 11:37-44.
9. Bisaga A., Comer S.D., Ward A.S., Popik P., Kleber H.D., Fischman M.W. The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans. Psychopharmacology 2001, 157:1-10.
10. Bowers M.S., Chen B.T., Chou J.K., Osborne M.P., Gass J.T., See R.E., et al. Acamprosate attenuates cocaine and cue-induced reinstatement of cocaine-seeking behavior in rats. Psychopharmacology 2007, 195:397-406.
11. Burattini C., McGeehan A.J., Griffin W.C., Gass J.T., Kinder J.R., Janak P.H., et al. A microdialysis study of extracellular levels of acamprosate and naltrexone in the rat brain following acute and repeated administration. Addict Biol 2008, 13:70-79.
12. Busse C.S., Brodkin J., Tattersall D., Anderson J.J., Warren N., Tehrani L., et al. The behavioral profile of the potent and selective mGlu5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) in rodent models of anxiety. Neuropsychopharmacology 2004, 29:1971-1979.
13. Chiamulera C., Epping-Jordan M.P., Zocchi A., Marcon C., Cottiny C., Tacconi S., et al. Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nat Neurosci 2001, 4:873-874.
14. Conn P.J., Pin J.P. Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 1997, 37:205-237.
15. Cortese B.M., Phan K.L. The role of glutamate in anxiety and related disorders. CNS Spectr 2005, 10:820-830.
16. Creeley C., Wozniak D.F., Labruyere J., Taylor G.T., Olney J.W. Low doses of memantine disrupt memory in adult rats. J Neurosci 2006, 26:3923-3932.
17. David H.N., Abraini J.H. Differential modulation of the D1-like- and D2-like dopamine receptor-induced locomotor responses by group II metabotropic glutamate receptors in the rat nucleus accumbens. Neuropharmacology 2001, 41:454-463.
18. David H.N., Ansseau M., Lemaire M., Abraini J.H. Nitrous oxide and xenon prevent amphetamine-induced carrier-mediated dopamine release in a memantine-like fashion and protect against behavioral sensitization. Biol Psychiatry 2006, 60:49-57.
19. Del Arco A., Martínez R., Mora F. Amphetamine increases extracellular concentrations of glutamate in the prefrontal cortex of the awake rat: a microdialysis study. Neurochem Res 1998, 23:1153-1158.
20. Fell M.J., Perry K.W., Falcone J.F., Johnson B.G., Barth V.N., Rash K.S., et al. In vitro and in vivo evidence for a lack of interaction with dopamine D2 receptors by the metabotropic glutamate 2/3 receptor agonists 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-bicaroxylate monohydrate (LY354740) and (-)-2-oxa-4-aminobicyclo[3.1.0] hexane-4,6-dicarboxylic acid (LY379268). J Pharmacol Exp Ther 2009, 331:1126-1136.
21. Ferreira R., Bassi G.S., Cabral A., Nobre M.J. Withdrawal from methylphenidate increases neural reactivity of dorsal midbrain. Neurosci Res 2010, 68:290-300.
22. Ferris P., Seward E., Dawson G.R. Interactions between LY354740, a group II metabotropic agonist and the GABA(A)-benzodiazepine receptor complex in the rat elevated plus-maze. J Psychopharmacol 2001, 15:76-82.
23. Fleckenstein A.E., Volz T.J., Riddle E.L., Gibb J.W., Hanson G.R. New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol 2007, 47:681-698.
24. Fletcher P.J. A comparison of the effects of risperidone, raclopride, and ritanserin on intravenous self-administration of d-amphetamine. Pharmacol Biochem Behav 1998, 60:55-60.
25. Gass J.T., Olive M.F. Glutamatergic substrates of drug addiction and alcoholism. Biochem Pharmacol 2008, 75:218-265.
26. Ginovart N., Farde L., Halldin C., Swahn C.G. Changes in striatal D2-receptor density following chronic treatment with amphetamine as assessed with PET in nonhuman primates. Synapse 1999, 31:154-162.
27. Goldstein R.Z., Volkow N.D. Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry 2002, 159:1642-1652.
28. Harris B.R., Prendergast M.A., Gibson D.A., Rogers D.T., Blanchard J.A., Holley R.C., et al. Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors. Alcohol Clin Exp Res 2002, 26:1779-1793.
29. Healy D.J., Meador-Woodruff J.H. Differential regulation, by MK-801, of dopamine receptor gene expression in rat nigrostriatal and mesocorticolimbic systems. Brain Res 1996, 708:38-44.
30. Herzig V., Capuani E.M., Kovar K.A., Schmidt W.J. Effects of MPEP on expression of food-, MDMA- or amphetamine-conditioned place preference in rats. Addict Biol 2005, 10:243-249.
31. Kalivas P.W. Cocaine and amphetamine-like psychostimulants: neurocircuitry and glutamate neuroplasticity. Dialogues Clin Neurosci 2007, 9:389-397.
32. Kalivas P.W. The glutamate homeostasis hypothesis of addiction. Nat Rev Neurosci 2009, 10:561-572.
33. Kampman K.M., Dackis C., Pettinati H.M., Lynch K.G., Sparkman T., O'Brien C.P. A double-blind, placebo-controlled pilot trial of acamprosate for the treatment of cocaine dependence. Addict Behav 2011, 36:217-221.
34. Karcz-Kubicha M., Jessa M., Nazar M., Plaznik A., Hartmann S., Parsons C.G., et al. Anxiolytic activity of glycine-B antagonists and partial agonists - no relation to intrinsic activity in the patch clamp. Neuropharmacology 1997, 36:1355-1367.
35. Kim J.H., Vezina P. The mGlu2/3 receptor agonist LY379268 blocks the expression of locomotor sensitization by amphetamine. Pharmacol Biochem Behav 2002, 73:333-337.
36. Kim J.H., Austin J.D., Tanabe L., Creekmore E., Vezina P. Activation of group II mGlu receptors blocks the enhanced drug taking induced by previous exposure to amphetamine. Eur J Neurosci 2005, 21:295-300.
37. Klodzinska A., Tatarczyńska E., Chojnacka-Wójcik E., Nowak G., Cosford N.D., Pilc A. Anxiolytic-like effects of MTEP, a potent and selective mGlu5 receptor agonist does not involve GABA(A) signaling. Neuropharmacology 2004, 47:342-350.
38. Koob G.F., Le Moal M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 2001, 24:97-129.
39. Kotlinska J., Bochenski M. The influence of various glutamate receptors antagonists on anxiety-like effect of ethanol withdrawal in a plus-maze test in rats. Eur J Pharmacol 2008, 598:57-63.
40. Kotlinska J., Liljequist S. A characterization of anxiolytic-like actions induced by the novel NMDA/glycine site antagonist, L-701,324. Psychopharmacology 1998, 135:175-181.
41. Krupitsky E.M., Neznanova O., Masalov D., Burakov A.M., Didenko T., Romanova T., et al. Effect of memantine on cue-induced alcohol craving in recovering alcohol-dependent patients. Am J Psychiatry 2007, 164:519-523.
42. Lea P.M., Faden A.I. Metabotropic glutamate receptor subtype 5 antagonists MPEP and MTEP. CNS Drug Rev 2006, 12:149-166.
43. Levy A.D., Kim J.J., Ellison G.D. Chronic amphetamine alters D-2 but not D-1 agonist-induced behavioral responses in rats. Life Sci 1988, 43:1207-1213.
44. Mcgeehan A.J., Olive M.F. The anti-relapse compound acamprosate inhibits the development of a conditioned place preference to ethanol and cocaine but not morphine. Br J Pharmacol 2003, 138:9-12.
45. Mcgeehan A.J., Olive M.F. Attenuation of cocaine-induced reinstatement of cocaine conditioned place preference by acamprosate. Behav Pharmacol 2006, 17:363-367.
46. Mcgeehan A.J., Janak P.H., Olive M.F. Effect of the mGluR5 antagonist 6-methyl-2-(phenylethynyl)pyridine (MPEP) on the acute locomotor stimulant properties of cocaine, d-amphetamine, and the dopamine reuptake inhibitor GBR12909 in mice. Psychopharmacology 2004, 174:266-273.
47. Nicoletti F., Bockaert J., Collingridge G.L., Conn P.J., Ferraguti F., Schoepp D.D., et al. Metabotropic glutamate receptors: from the workbench to the bedside. Neuropharmacology 2011, 60:1017-1041.
48. Olive M.F. Metabotropic glutamate receptor ligands as potential therapeutics for addiction. Curr Drug Abuse Rev 2009, 2:83-98.
49. Olive M.F., Cleva R.M., Kalivas P.W., Malcolm R.J. Glutamatergic medications for the treatment of drug and behavioral addictions. Pharmacol Biochem Behav 2012, 100:801-810.
50. Parsons C.G., Stöffler A., Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worse. Neuropharmacology 2007, 53:699-723.
51. Peterson J.D., Wolf M.E., White F.J. Altered responsiveness of medial prefrontal cortex neurons to glutamate and dopamine after withdrawal from repeated amphetamine treatment. Synapse 2000, 36:342-344.
52. Pietraszek M., Sukhanov I., Maciejak P., Szyndler J., Gravius A., Wisłowska A., et al. Anxiolytic-like effects of mGlu1 and mGlu5 receptor antagonists in rats. Eur J Pharmacol 2005, 514:25-34.
53. Plaznik A., Palejko W., Nazar M., Jessa M. Effects of antagonists at the NMDA receptor complex in two models of anxiety. J Eur Neuropsychopharmacol 1994 Dec, 4(4):503-512.
54. Rammes G., Mahal B., Putzke J., Parsons C., Spielmanns P., Pestel E., et al. The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801. Neuropharmacology 2001, 40:749-760.
55. Rammes G., Danysz W., Parsons C.G. Pharmacodynamics of memantine: an update. Curr Neuropharmacol 2008, 6:55-78.
56. Rouillon C., Degoulet M., Chevallier K., Abraini J.H., David H.N. Modulation by group I mGLU receptor activation and group III mGLU receptor blockade of locomotor responses induced by D1-like and D2-like receptor agonists in the nucleus accumbens. Brain Res 2008, 1198:44-54.
57. Sanacora G., Zarate C.A., Krystal J.H., Manji H.K. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 2008, 7:426-437.
58. Schoepp D.D. Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. J Pharmacol Exp Ther 2001, 299:12-20.
59. Seeman P., Tallerico T., Ko F., Tenn C., Kapur S. Amphetamine-sensitized animals show a marked increase in dopamine D2 high receptors occupied by endogenous dopamine, even in the absence of acute challenges. Synapse 2002, 46:235-239.
60. Seeman P., Caruso C., Lasaga M. Memantine agonist action at dopamine D2 high receptors. Synapse 2008, 62:149-153.
61. Seeman P., Caruso C., Lasaga M. Dopamine partial agonist actions of the glutamate receptor agonists LY 354,740 and LY 379,268. Synapse 2008, 62:154-158.
62. Spooren W., Ballard T., Gasparini F., Amalric M., Mutel V., Schreiber R. Insight into the function of Group I and Group II metabotropic glutamate (mGlu) receptors: behavioural characterization and implications for the treatment of CNS disorders. Behav Pharmacol 2003, 14:257-277.
63. Stoker A.K., Olivier B., Markou A. Involvement of metabotropic glutamate receptor 5 in brain reward deficits associated with cocaine and nicotine withdrawal and somatic signs of nicotine withdrawal. Psychopharmacology 2012, 221:317-327.
64. Sulzer D., Sonders M.S., Poulsen N.W., Galli A. Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 2005, 75:406-433.
65. Swanson C.J., Bures M., Johnson M.P., Linden A.M., Monn J.A., Schoepp D.D. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat Rev Drug Discov 2005, 4:131-144.
66. Talalaenko A.N., Gordienko D.V., Pankrat'ev D.V., Zinkovich I.I., Krivobok G.K. The role of neurochemical mechanisms of ventromedial hypothalamus in various models of anxiety in rats. Bull Exp Biol Med 2001, 131:38-40.
67. Teter C.J., McCabe S.E., LaGrange K., Cranford J.A., Boyd C.J. Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration. Pharmacotherapy 2006, 26:1501-1510.
68. Tzschentke T.M., Schmidt W.J. Glutamatergic mechanisms in addiction. Mol Psychiatry 2003, 8:373-382.
69. Vuong S.M., Oliver H.A., Scholl J.L., Oliver K.M., Forster G.L. Increased anxiety-like behavior of rats during amphetamine withdrawal is reversed by CRF2 receptor antagonism. Behav Brain Res 2010, 208:278-281.
70. Wall P.M., Messier C. Ethological confirmatory factor analysis of anxiety-like behaviour in the murine elevated plus-maze. Behav Brain Res 2000, 114:199-212.
71. Wang M., Wong A.H., Liu F. Interactions between NMDA and dopamine receptors: a potential therapeutic target. Brain Res 2012, 1476:154-163.
72. Witkiewitz K., Saville K., Hamreus K. Acamprosate for treatment of alcohol dependence: mechanisms, efficacy, and clinical utility. Ther Clin Risk Manag 2012, 8:45-53.
73. Wolf M.E. The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants. Prog Neurobiol 1998, 54:679-720.
74. Xue C.J., Ng J.P., Li Y., Wolf M.E. Acute and repeated systemic amphetamine administration: effects on extracellular glutamate, aspartate, and serine levels in rat ventral tegmental area and nucleus accumbens. J Neurochem 1996, 67:352-363.
75. Zysk J.R., Widzowski D., Sygowski L.A., Knappenberger K.S., Spear N., Elmore C.S., et al. Absence of direct effects on the dopamine D2 receptor by mGluR2/3-selective receptor agonists LY 354,740 and LY 379,268. Synapse 2011, 65:64-68.